Publications
Publications 2026 - 2050 de 33557
| Titre | DOI |
|---|---|
|
Adjustable high-repetition-rate pulse trains in a passively-mode-locked fiber laser R.Si Fodil; F. Amrani; C. Yang; A. Kellou; P. Grelu 2016 |
10.1103/PhysRevA.94.013813 |
|
Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial S.M. de Boer; M.E. Powell; L. Mileshkin; D. Katsaros; P. Bessette; C. Haie-Meder; P.B. Ottevanger; J.A. Ledermann; P. Khaw; A. Colombo; A. Fyles; M.H. Baron; I.M. Jurgenliemk-Schulz; H.C. Kitchener; H.W. Nijman; G. Wilson; S. Brooks; S. Carinelli; D. Provencher; C. Hanzen; L.C.H.W. Lutgens; V.T.H.B.M. Smit; N. Singh; V. Do; R. D'Amico; R.A. Nout; A. Feeney; K.W. Verhoeven-Adema; H. Putter; C.L. Creutzberg; P.O.R.T.E.C.Study Grp 2018 |
10.1016/S1470-2045(18)30079-2 |
|
Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial S.M. de Boer; M.E. Powell; L. Mileshkin; D. Katsaros; P. Bessette; C. Haie-Meder; P.B. Ottevanger; J.A. Ledermann; P. Khaw; R. D'Amico; A. Fyles; M.H. Baron; I.M. Jurgenliemk-Schulz; H.C. Kitchener; H.W. Nijman; G. Wilson; S. Brooks; S. Gribaudo; D. Provencher; C. Hanzen; R.F. Kruitwagen; V.T.H.B.M. Smit; N. Singh; V. Do; A. Lissoni; R.A. Nout; A. Feeney; K.W. Verhoeven-Adema; H. Putter; C.L. Creutzberg; P.O.R.T.E.C.Study Grp 2019 |
10.1016/S1470-2045(19)30395-X |
|
Adjuvant chemotherapy after preoperative (chemo) radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data A.J. Breugom; M. Swets; J.F. Bosset; L. Collette; A. Sainato; L. Cionini; R. Glynne-Jones; N. Counsell; E. Bastiaannet; C.B.M. van den Broek; G.J. Liefers; H. Putter; C.J.H. van de Velde 2015 |
10.1016/S1470-2045(14)71199-4 |
|
Adjuvant chemotherapy and radiation therapy (RT) versus RT alone for women with high-risk endometrial cancer: Toxicity and quality-of-life results of the randomized PORTEC-3 trial. C.L. Creutzberg; S.M. de Boer; H. Putter; M. Powell; L.R. Mileshkin; D. Katsaros; P. Bessette; C. Haie-Meder; J.A. Ledermann; P.B. Ottevanger; P. Khaw; A. Colombo; A.W. Fyles; M.H. Baron; H.W. Nijman; R.A. Nout; V.T.H.B.M. Smit; K. Verhoeven-Adema; R.F.P.M. Kruitwagen; H.C. Kitchener 2015 |
10.1200/jco.2015.33.15_suppl.5501 |
|
Adjuvant chemotherapy for local relapse breast cancer X. Pivot 2014 |
10.1016/S1470-2045(13)70610-7 |
|
Adjuvant chemotherapy for rectal cancer Reply J.F. Bosset; L. Collette 2014 |
10.1016/S1470-2045(14)70128-7 |
|
Adjuvant chemotherapy for residual disease after neoadjuvant chemotherapy for muscle invasive urothelial cancer (MIUC) L.Christine Harshman; L. Werner; Y.N. Wong; E.Y. Yu; A.Shivaram Alva; S.J. Crabb; T. Powles; J.E. Rosenberg; J. Baniel; U.N. Vaishampayan; D.R. Berthold; S. Ladoire; S.A. Hussain; M.I. Milowsky; N. Agarwal; A. Necchi; S.Kumar Pal; F. Recine; J. Bellmunt; M.D. Galsky; R.I.S.C. Investigators 2015 |
10.1200/jco.2015.33.15_suppl.4524 |
|
Adjuvant chemotherapy in elderly breast cancer patients: Pattern of use and impact on overall survival A. Berthelot; A. De Nonneville; J.M. Classe; M. Cohen; F. Reyal; C. Mazouni; M.P. Chauvet; A. Martinez; N. Chopin; E. Darai; C. Coutant; R. Rouzier; A.S. Azuar; P. Guimbergues; T. de Lara; R. Villet; M. Bannier; A. Goncalves; G. Houvenaeghel 2019 |
|
|
Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit A. de Nonneville; C. Jauffret; A. Goncalves; J.M. Classe; M. Cohen; F. Reyal; C. Mazouni; M.P. Chauvet; N. Chopin; P.E. Colombo; E. Jouve; E. Darai; R. Rouzier; C. Cotant; P. Gimbergues; A.S. Azuar; C.T. de Lara; E. Lambaudie; G. Houvenaeghel 2019 |
10.1007/s10549-019-05160-9 |
|
Adjuvant Chemotherapy in Rectal Cancer after Chemoradiotherapy J. Boustani; M. Caubet; J.F. Bosset 2016 |
10.1016/j.clon.2015.11.004 |
|
Adjuvant chemotherapy versus perioperative chemotherapy (CTx) for resectable gastric signet ring cell (SRC) gastric cancer: A multicenter, randomized phase II study (PRODIGE 19). C. Eveno; A. Adenis; O. Bouche; K. Le Malicot; V. Hautefeuille; R. Faroux; A.Thirot Bidault; J. Egreteau; B. Meunier; M. Mabro; N. Carrere; N. Barriere; M. Ben Abdelghani; F. Mauvais; F. Di Fiore; D. Malka; S. Manfredi; G. Piessen 2019 |
10.1200/JCO.2019.37.15_suppl.4019 |
|
Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study T. Andre; A. De Gramont; D. Vernerey; B. Chibaudel; F. Bonnetain; A. Tijeras-Raballand; A. Scriva; T. Hickish; J. Tabernero; J.Luc Van Laethem; M. Banzi; E. Maartense; E. Shmueli; G.U. Carlsson; W. Scheithauer; D. Papamichael; M. Moeehler; S. Landolfi; P. Demetter; S. Colote; C. Tournigand; C. Louvet; A. Duval; J.F. Flejou; A. de Gramont 2015 |
10.1200/JCO.2015.63.4238 |
|
Adjuvant FOLFOX plus /- cetuximab in full RAS and BRAF wildtype stage III colon cancer patients J. Taieb; R. Balogoun; K. Le Malicot; J. Tabernero; E. Mini; G. Folprecht; J.L. Van Laethem; J.F. Emile; C. Mulot; S. Fratte; C.B. Levache; L. Saban-Roche; J. Thaler; L.N. Petersen; J. Bridgewater; G. Perkins; C. Lepage; E. Van Cutsem; A. Zaanan; P. Laurent-Puig; P.E.T.A.C.C.8 Investigators 2017 |
10.1093/annonc/mdw687 |
|
Adjuvant FOLFOX plus cetuximab vs FOLFOX in full RAS and BRAF wild type stage III colon cancer patients: Results from the PETACC8 trial J. Taieb; K. Le Malicot; R. Balogoum; J. Tabernero; E. Mini; G. Folprecht; J.L. van Laethem; J.F. Emile; C. Mulot; S. Fratte; C.B. Levache; L. Saban-Roche; J. Thaler; N. Petersen; E. Sanchez; J. Bridgewater; G. Perkins; C. Lepage; A. Zaanan; P. Laurent-Puig 2016 |
10.1093/annonc/mdw370.10 |
|
Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: Pooled analysis of the BCAT and PRODIGE-12 studies J. Edeline; S. Hirano; A. Bertaut; M. Konishi; M. Benabdelghani; K. Uesaka; J. Watelet; M. Ohtsuka; P. Hammel; Y. Kaneoka; J.P. Joly; M. Yamamoto; C. Jouffroy; Y. Ambo; C. Louvet; M. Ando; D. Malka; M. Nagino; J.M. Phelip; T. Ebata 2020 |
10.1016/j.annonc.2020.08.033 |
|
Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial J. Edeline; F. Bonnetain; J.M. Phelip; J. Watelet; P. Hammel; J.P. Joly; M. Benabdelghani; L. Fartoux; K. Bouhier-Leporrier; J.L. Jouve; R. Faroux; V. Guerin-Meyer; E. Assenat; J.F. Seitz; D. Malka; C. Louvet; A. Bertaut; B. Juzyna; T. Stanbury; E. Boucher 2017 |
|
|
Adjuvant GEMOX for biliary tract cancer: Updated relapse-free survival and first overall survival results of the randomized PRODIGE 12-ACCORD 18 (UNICANCER GI) phase III trial J. Edeline; F. Bonnetain; J.M. Phelip; J. Watelet; P. Hammel; J.P. Joly; M. Benabdelghani; L. Fartoux; K. Bouhier-Leporrier; J.L. Jouve; R. Faroux; V. Guerin-Meyer; E. Assenat; J.F. Seitz; D. Malka; C. Louvet; A. Bertaut; B. Juzyna; T. Stanbury; E. Boucher 2017 |
|
|
Adjuvant hormonal therapy for early breast cancer: an epidemiologic study of medication adherence C. Pourcelot; E. Orillard; G. Nallet; C. Dirand; F. Billion-Rey; G. Barbier; S. Chouk; S. Limat; P. Montcuquet; J. Henriques; S. Paget-Bailly; A. Anota; L. Chaigneau; V. Nerich 2018 |
10.1007/s10549-018-4676-3 |
|
Adjuvant hormonal therapy for early breast cancer: Assessment of patients' satisfaction J. Vardanega; J. Henriques; C. Pourcelot; C. Dirand; G. Nallet; A. Bredart; A. Anota; L. Chaigneau; E. Curtit; S. Limat; S. Paget-Bailly; V. Nerich 2019 |
10.1016/j.bulcan.2019.08.019 |
|
Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma T.K. Choueiri; P. Tomczak; S.H. Park; B. Venugopal; T. Ferguson; Y.H. Chang; J. Hajek; S.N. Symeonides; J.L. Lee; N. Sarwar; A. Thiery-Vuillemin; M. Gross-Goupil; M. Mahave; N.B. Haas; P. Sawrycki; H. Gurney; C. Chevreau; B. Melichar; E. Kopyltsov; A. Alva; J.M. Burke; G. Doshi; D. Topart; S. Oudard; H. Hammers; H. Kitamura; J. Bedke; R.F. Perini; P. Zhang; K. Imai; J. Willemann-Rogerio; D.I. Quinn; T. Powles; K.E.Y.N.O.T.E.564 Investigators 2021 |
10.1056/NEJMoa2106391 |
|
Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability K.H. Jung; B. Ataseven; M. Verrill; X. Pivot; M. De Laurentiis; N. Al-Sakaff; S. Lauer; M. Shing; J. Gligorov; H.A. Azim 2016 |
10.1093/annonc/mdw364.67 |
|
Adjuvant treatments for gastric cancer: From practice guidelines to clinical practice A.Marie Bouvier; G. Crehange; C. Azelie; N. Cheynel; J.Louis Jouve; L. Bedenne; J. Faivre; C. Lepage; P. Maingon 2014 |
10.1016/j.dld.2013.07.003 |
|
Adjuvant-induced arthritis is a relevant model to mimic coronary and myocardial impairments in rheumatoid arthritis R. Bordy; J. Moretto; S. Devaux; D. Wendling; K. Moretto-Riedweg; C. Demougeot; P. Totoson 2021 |
10.1016/j.jbspin.2020.09.001 |
|
ADL disability and death in dementia in a French population-based cohort: New insights with an illness-death model F. Delva; C. Touraine; P. Joly; A. Edjolo; H. Amieva; C. Berr; O. Rouaud; C. Helmer; K. Peres; J.F. Dartigues 2016 |
10.1016/j.jalz.2016.03.007 |